The biotech will stop developing two drugs and lay off nearly three-quarters of its staff after its lead therapy wasn’t as potent in early testing as the company expected.

Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines and unprecedented lipid nanoparticle (LNP) delivery solutions for oncology and ...

Shares of fuel cell and hydrogen specialist Plug Power (NASDAQ: PLUG) may have nudged higher in the beginning of the year, ...

Residents impacted by the California wildfires may get inundated with calls from people offering to handle their claims for ...

Hong Kong’s insurance sector has seen a surge in phishing scams, prompting repeated warnings from the IA. The regulator ...

Illumina has begun rolling out a series of updates to its top-of-the-line DNA sequencer models, with the goal of making the ...

We're approaching the evening hours of CES, but companies are still showing off what they have up their sleeves. Among the companies showcasing their ...

A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy that targets ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Multiple wildfires, including the Palisades Fire and Eaton Fire, are raging across southern California early Thursday, ...

Record Performance: Hydreight reported $6.12 million in revenue for Q3 2024, marking a 54% year-over-year increase. Our achievements led to Hydreight being ranked 56th on Deloitte’s Technology Fast ...